NEW YORK (360Dx) – Australian proteomics firm Proteomics International Laboratories said today it has licensed US sales of its PromarkerD test for diabetic kidney disease to PrismHealthDx (PHDx).

According to Proteomics International, Austin, Texas-based PHDx will roll out a national launch of the test, which uses mass spectrometry to measure blood-based proteins to predict diabetes patients' risk of developing diabetic kidney disease. PHDx will offer the test as a laboratory-developed test out of its CLIA facilities.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 

Sponsored by

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.